Predictors of HBsAg seroclearance in HBeAg-Negative chronic hepatitis B patients

Digestion

Volumn 84, Issue SUPPL. 1, 2011, Pages 23-28

  Kwak, Min Sun ^a   Cho, Eun Ju ^a   Jang, Eun Sun ^a   Lee, Jeong Hoon ^a   Yu, Su Jong ^a   Kim, Yoon Jun ^a   Yoon, Jung Hwan ^a   Lee, Hyo Suk ^a  

^a Seoul National University   (South Korea)

Author keywords

Age; Chronic hepatitis B; HBsAg seroclearance; Serum HBV DNA; Sustained inactive phase

Indexed keywords

ANTIVIRUS AGENT; HEPATITIS B SURFACE ANTIGEN; VIRUS DNA;

ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; CHRONIC HEPATITIS; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEPATITIS B; HEPATITIS B SURFACE ANTIGEN NEGATIVE CHRONIC HEPATITIS B; HEPATITIS B SURFACE ANTIGEN SEROCLEARANCE; HEPATITIS B VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PREDICTION; PRIORITY JOURNAL; SEROLOGY; VIRAL CLEARANCE;

ADOLESCENT; ADULT; AGE FACTORS; ANTIVIRAL AGENTS; COHORT STUDIES; DNA, VIRAL; FEMALE; FOLLOW-UP STUDIES; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; YOUNG ADULT;

EID: 83755224357     PISSN: 00122823     EISSN: 14219867     Source Type: Journal    
DOI: 10.1159/000333211     Document Type: Article

References (26)

1. Yim HJ, Lok AS: Natural history of chronic hepatitis B virus infection: what we knew in 1981 and what we know in 2005. Hepatology 2006; 43:S173-S181.
2. McMahon BJ: The natural history of chronic hepatitis B virus infection. Hepatology 2009; 49:S45-S55.
3. Liaw YF: Natural history of chronic hepatitis B virus infection and long-term outcome under treatment. Liver Int 2009; 29(suppl 1):100-107.
4. Chu CM, Liaw YF: HBsAg seroclearance in asymptomatic carriers of high endemic areas: appreciably high rates during a longterm follow-up. Hepatology 2007; 45: 1187-1192.
5. McMahon BJ, Holck P, Bulkow L, Snowball M: Serologic and clinical outcomes of 1536 Alaska natives chronically infected with hepatitis B virus. Ann Intern Med 2001; 135: 759-768. (Pubitemid 33051260)
6. Liu J, Yang HI, Lee MH, Lu SN, Jen CL, Wang LY, You SL, Iloeje UH, Chen CJ: Incidence and determinants of spontaneous hepatitis B surface antigen seroclearance: a community- based follow-up study. Gastroenterology 2010; 139: 474-482.
7. Liaw YF, Sheen IS, Chen TJ, Chu CM, Pao CC: Incidence, determinants and significance of delayed clearance of serum HBsAg in chronic hepatitis B virus infection: a prospective study. Hepatology 1991; 13: 627-631.
8. Yang YF, Zhao W, Xia HM, Zhong YD, Huang P, Wen J: Long-term efficacy of interferon lpha therapy on hepatitis B viral replication in patients with chronic hepatitis b: a meta-analysis. Antiviral Res 2010; 85: 361-365.
9. Yuen MF, Wong DK, Sablon E, Tse E, Ng IO, Yuan HJ, Siu CW, Sander TJ, Bourne EJ, Hall JG, Condreay LD, Lai CL: HBsAg seroclearance in chronic hepatitis B in the Chinese: virological, histological, and clinical aspects. Hepatology 2004; 39: 1694-1701. (Pubitemid 38702671)
10. Lok AS, McMahon BJ: Chronic hepatitis B: update 2009. Hepatology 2009; 50: 661-662.
11. Liaw YF, Leung N, Kao JH, Piratvisuth T, Gane E, Han KH, Guan R, Lau GK, Locarnini S: Asian-pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2008; 2: 263-283.
12. European Association for the Study of the Liver: EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009; 50: 227-242.
13. Kim H, Jee YM, Song BC, Shin JW, Yang SH, Mun HS, Kim HJ, Oh EJ, Yoon JH, Kim YJ, Lee HS, Hwang ES, Cha CY, Kook YH, Kim BJ: Molecular epidemiology of hepatitis B virus (HBV) genotypes and serotypes in patients with chronic HBV infection in Korea. Intervirology 2007; 50: 52-57. (Pubitemid 46005272)
14. Bae SH, Yoon SK, Jang JW, Kim CW, Nam SW, Choi JY, Kim BS, Park YM, Suzuki S, Sugauchi F, Mizokami M: Hepatitis B virus genotype c prevails among chronic carriers of the virus in Korea. J Korean Med Sci 2005; 20: 816-820. (Pubitemid 41587239)
15. Cho JH, Yoon KH, Lee KE, Park DS, Lee YJ, Moon HB, Lee KR, Choi CS, Cho EY, Kim HC: Distribution of hepatitis B virus genotypes in Korea (in Korean). Korean J Hepatol 2009; 15: 140-147.
16. Cha CH, Sohn YH, Ko SY, Oh HB: Subgenotype and serotype analysis of hepatitis B virus in Korean chronic hepatitis B patients under treatment (in Korean). Korean J Lab Med 2009; 29: 53-58.
17. Chae HB, Kim JH, Kim JK, Yim HJ: Current status of liver diseases in Korea: hepatitis B. Korean J Hepatol 2009; 15(suppl 6):S13-S24.
18. Jaroszewicz J, Calle Serrano B, Wursthorn K, Deterding K, Schlue J, Raupach R, Flisiak R, Bock CT, Manns MP, Wedemeyer H, Cornberg M: Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: a European perspective. J Hepatol 2010; 52: 514-522.
19. Nguyen T, Thompson AJ, Bowden S, Croagh C, Bell S, Desmond PV, Levy M, Locarnini SA: Hepatitis B surface antigen levels during the natural history of chronic hepatitis B: a perspective on Asia. J Hepatol 2010; 52: 508-513.
20. Jeong S, Yim HW, Bae SH, Lee WC: Changes of hepatitis B surface antigen seroprevalence in Korea, 1998-2005. Korean J Epidemiol 2008; 30: 119-127.
21. National Health and Nutrition Survey in Korea. http://cdc.go.kr.
22. Chan HL, Wong VW, Wong GL, Tse CH, Chan HY, Sung JJ: A longitudinal study on the natural history of serum hepatitis B surface antigen changes in chronic hepatitis B. Hepatology 2010; 52: 1232-1241.
23. Arase Y, Ikeda K, Suzuki F, Suzuki Y, Saitoh S, Kobayashi M, Akuta N, Someya T, Hosaka T, Sezaki H, Kumada H: Long-term outcome after hepatitis B surface antigen seroclearance in patients with chronic hepatitis B. Am J Med 2006; 119: 71 e79-e16.
24. Zoulim F: Antiviral therapy of chronic hepatitis B: can we clear the virus and prevent drug resistance? Antivir Chem Chemother 2004; 15: 299-305. (Pubitemid 39656966)
25. Werle-Lapostolle B, Bowden S, Locarnini S, Wursthorn K, Petersen J, Lau G, Trepo C, Marcellin P, Goodman Z, Delaney WE 4th, Xiong S, Brosgart CL, Chen SS, Gibbs CS, Zoulim F: Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 2004; 126: 1750-1758. (Pubitemid 38736340)
26. Wursthorn K, Lutgehetmann M, Dandri M, Volz T, Buggisch P, Zollner B, Longerich T, Schirmacher P, Metzler F, Zankel M, Fischer C, Currie G, Brosgart C, Petersen J: Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B. Hepatology 2006; 44: 675-684. (Pubitemid 44433724)